Palatin Technologies Provides Mid-Calendar Year Corporate Update
– Vyleesi™ Approved by FDA for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) – Approximately $102 Million in Pro Forma Cash and Equivalents at June 30, 2019 CRANBURY, N.J., July 1, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with …
Palatin Technologies Provides Mid-Calendar Year Corporate Update Read More »